Blueprint Medicines (Blueprint Medicines) Interest Expense : $-45.1 Mil (TTM As of Mar. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Blueprint Medicines Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Blueprint Medicines's interest expense for the three months ended in Mar. 2024 was $ -15.1 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $-45.1 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Blueprint Medicines's Operating Income for the three months ended in Mar. 2024 was $ -78.8 Mil. Blueprint Medicines's Interest Expense for the three months ended in Mar. 2024 was $ -15.1 Mil. Blueprint Medicines did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Blueprint Medicines Interest Expense Historical Data

The historical data trend for Blueprint Medicines's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines Interest Expense Chart

Blueprint Medicines Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

-16.77

-18.79

Blueprint Medicines Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial															-11.72	-11.75	-13.14	-5.17	-15.07

Blueprint Medicines Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-45.1 Mil.

Blueprint Medicines (NAS:BPMC) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Blueprint Medicines's Interest Expense for the three months ended in Mar. 2024 was $-15.1 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-78.8 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $287.7 Mil.

Blueprint Medicines's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

Blueprint Medicines did not have earnings to cover the interest expense.

The higher the ratio, the stronger the company's financial strength is.

Blueprint Medicines (Blueprint Medicines) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (NAS:BPMC) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

2L9:Germany 2L9:Germany

Address

45 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.blueprintmedicines.com

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

Executives

Ariel Hurley	officer: Principal Accounting Officer	C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Jeffrey W. Albers	director, officer: CEO & President	BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Christopher K. Murray	officer: SVP, Technical Operations	C/O BLUEPRINT MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Fouad Namouni	officer: President, R and D	535 BOYLSTON ST., 2ND FLOOR, BOSTON MA 02116
L. Becker Hewes	officer: Chief Medical Officer	C/O BLUEPRINT MEDICINES, CORPORATION, CAMBRIDGE MA 02139
Percy H. Carter	officer: Chief Scientific Officer	C/O BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Philina Lee	officer: Chief Commercial Officer	C/O FUSION PHARMACEUTICALS, INC., 270 LONGWOOD ROAD SOUTH, HAMILTON D0 L8P OA6
Christina Rossi	officer: Chief Commercial Officer	45 SIDNEY STREET, BLUEPRINT MEDICINES CORPORATION, CAMBRIDGE MA 02139
Tracey L Mccain	officer: EVP and Chief Legal Officer	C/O BLUEPRINTS MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
Michael Landsittel	officer: Principal FAO	BLUEPRINT MEDICINES CORP., 214 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142
Debra Durso-bumpus	officer: Chief People Officer	C/O BLUEPRINT MEDICINES CORORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Kate Haviland	officer: Chief Business Officer	BLUEPRINT MEDICINES CORPORATION, 38 SIDNEY STREET, SUITE 200, CAMBRIDGE MA 02139
John Tsai	director	BLUEPRINT MEDICINES CORPORATION, 45 SIDNEY STREET, CAMBRIDGE MA 02139
Habib J Dable	director	C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139
George Demetri	director	BLUEPRINT MEDICINES CORP., 215 FIRST STREET, SUITE 340/350, CAMBRIDGE MA 02142